RA-9

RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER) -stress responses in ovarian cancer cells[1].

Product Specifications

CAS Number

[919091-63-7]

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; Deubiquitinase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ra-9.html

Concentration

10mM

Purity

98.57

Solubility

DMSO : 4.17 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=C1/C(CNC/C1=C\C2=CC=C([N+]([O-])=O)C=C2)=C/C3=CC=C([N+]([O-])=O)C=C3

Molecular Formula

C19H15N3O5

Molecular Weight

365.34

Precautions

H302

References & Citations

[1]Coughlin K, et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res. 2014;20 (12) :3174-3186.